Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Rating of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have earned a consensus rating of “Hold” from the sixteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, nine have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $475.90.

MEDP has been the subject of several research analyst reports. Cowen reissued a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Jefferies Financial Group boosted their price objective on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Zacks Research upgraded Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Finally, Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 36,196 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares in the company, valued at $440,587,744.10. This represents a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Jesse J. Geiger sold 21,503 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at $8,934,900. This represents a 58.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 116,211 shares of company stock valued at $63,569,958 in the last ninety days. 20.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. boosted its holdings in shares of Medpace by 16.1% during the first quarter. Crossmark Global Holdings Inc. now owns 2,270 shares of the company’s stock valued at $692,000 after acquiring an additional 315 shares during the period. Alps Advisors Inc. lifted its position in Medpace by 10.0% in the 1st quarter. Alps Advisors Inc. now owns 1,098 shares of the company’s stock valued at $335,000 after purchasing an additional 100 shares during the last quarter. Covey Capital Advisors LLC bought a new stake in Medpace in the 1st quarter valued at about $1,261,000. Joseph Group Capital Management boosted its position in shares of Medpace by 15.3% during the first quarter. Joseph Group Capital Management now owns 4,173 shares of the company’s stock worth $1,271,000 after buying an additional 553 shares during the period. Finally, Oxbow Advisors LLC bought a new position in Medpace in the 1st quarter worth approximately $2,701,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 0.5%

Shares of MEDP opened at $589.15 on Friday. The firm has a market cap of $16.60 billion, a price-to-earnings ratio of 41.20, a PEG ratio of 2.67 and a beta of 1.42. The business’s 50 day moving average is $527.73 and its two-hundred day moving average is $412.36. Medpace has a 52-week low of $250.05 and a 52-week high of $625.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts expect that Medpace will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.